Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations
Isaacs, Randi, Chen, Xueying, Graus Porta, Diana, Parker, Katie, Yu, Kun and Porter, Dale (2018) Efficacy of BGJ398, a fibroblast growth factor receptor (FGFR) 1-3 inhibitor, in patients with previously treated advanced urothelial carcinoma with FGFR3 alterations. Cancer discovery. ISSN 2159-8290; 2159-8274
Abstract
We report the activity of BGJ398, a potent and selective pan-fibroblast growth factor receptor (FGFR) antagonist, in patients with metastatic urothelial carcinoma bearing relevant genomic alterations. Patients (N = 67) who had received prior platinum chemotherapy with a diverse array of FGFR3 alterations were enrolled. The majority (70.1%) had ≥2 prior antineoplastic therapies. BGJ398 was administered at 125 mg oral daily on a 3 week on, 1 week off schedule until the time of unacceptable toxicity or progression. The primary endpoint was response rate (RR). Amongst 67 evaluable patients, an overall RR of 25.4% was observed and an additional 39% of patients had disease stabilization, translating to a clinical benefit rate of 64.2%. The most common treatment-emergent toxicities encountered with therapy included hyperphosphatemia, elevated creatinine, fatigue and constipation. Further examination of BGJ398 in this disease setting is therefore warranted.
Item Type: | Article |
---|---|
Date Deposited: | 06 Jul 2018 00:45 |
Last Modified: | 06 Jul 2018 00:45 |
URI: | https://oak.novartis.com/id/eprint/34650 |